Dr Meghan Brown Schaefer, MD | |
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
(414) 805-0805 | |
(414) 955-0122 |
Full Name | Dr Meghan Brown Schaefer |
---|---|
Gender | Female |
Speciality | Urology |
Experience | 11 Years |
Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1689917650 | NPI | - | NPPES |
1689917650 | Medicaid | WI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 036145934 (Illinois) | Secondary |
208800000X | Urology | 62944 (Wisconsin) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
Froedtert Andthe Medical College Of Wisconsin Community Physicians Inc | 3678760063 | 1040 |
News Archive
Giving patients a short course of corticosteroids after they have been discharged from hospital for an asthma attack reduces the chances of a relapse, a Cochrane Systematic Review has found. Giving the steroids also reduces their use of inhalers.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don't qualify for low-dose CT scans, according to a group of Mayo Clinic researchers.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
› Verified 5 days ago
Entity Name | The Medical College Of Wisconsin Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Giving patients a short course of corticosteroids after they have been discharged from hospital for an asthma attack reduces the chances of a relapse, a Cochrane Systematic Review has found. Giving the steroids also reduces their use of inhalers.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don't qualify for low-dose CT scans, according to a group of Mayo Clinic researchers.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
› Verified 5 days ago
Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Giving patients a short course of corticosteroids after they have been discharged from hospital for an asthma attack reduces the chances of a relapse, a Cochrane Systematic Review has found. Giving the steroids also reduces their use of inhalers.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don't qualify for low-dose CT scans, according to a group of Mayo Clinic researchers.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Meghan Brown Schaefer, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-0805 | Dr Meghan Brown Schaefer, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-0805 |
News Archive
Giving patients a short course of corticosteroids after they have been discharged from hospital for an asthma attack reduces the chances of a relapse, a Cochrane Systematic Review has found. Giving the steroids also reduces their use of inhalers.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don't qualify for low-dose CT scans, according to a group of Mayo Clinic researchers.
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved.
› Verified 5 days ago
Mark Ehlers, Urology Medicare: Medicare Enrolled Practice Location: 2801 W Kinnickinnic River Pkwy Ste 330, Milwaukee, WI 53215 Phone: 414-649-1280 Fax: 414-649-1288 | |
Dr. Michael L Guralnick, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Department Of Urology, Milwaukee, WI 53226 Phone: 414-805-0805 Fax: 414-805-0771 | |
Dr. Arman Cicic, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 2600 N Mayfair Rd Ste 580, Milwaukee, WI 53226 Phone: 414-476-0430 | |
Dr. Pedro M. Banda, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2311 N Prospect Ave, Milwaukee, WI 53211 Phone: 414-319-3000 Fax: 414-319-3087 | |
Dr. Jay I Sandlow, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Dept Of Urology, Milwaukee, WI 53226 Phone: 414-805-0805 Fax: 414-805-0771 | |
Joshua Alan Bodie, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Department Of Urology, Milwaukee, WI 53226 Phone: 414-805-0805 Fax: 414-805-0771 | |
Mr. Michael Ernst Mitchell, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9000 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-3666 |